Merck & Co., Inc., Rahway, NJ USA, which is known as MSD outside the U.S. and Canada

Pharmaceuticals, Biotechnology and Life Sciences

Targets set1.5°CNet-Zero: Targets set

SBTI ID

40005417

Informations générales

Localisation

United States of America

Northern America

Secteur d'activité

Pharmaceuticals, Biotechnology and Life Sciences

Type d'organisation

Corporate

Dernière mise à jour

10/07/2025

Objectifs à court terme (Near-Term)
Engagement de réduction des émissions à horizon 2030

Statut

Targets set

Classification

1.5°C

Année cible

2030

Progression vers l'objectif73%
2015 (année de référence)2030
Objectifs à long terme (Long-Term)
Engagement de réduction des émissions à horizon 2045

Statut

Targets set

Classification

1.5°C

Année cible

2045

Progression vers l'objectif37%
2015 (année de référence)2045
Description complète des objectifs

Overall Net-Zero Target: Merck & Co., Inc., Rahway, New Jersey, U.S.A., which is known as MSD outside the U.S. and Canada commits to reach net-zero greenhouse gas emissions across the value chain by 2045. Near-Term Targets: Merck & Co., Inc., Rahway, NJ, U.S.A., which is known as MSD outside the U.S. and Canada commits to reduce absolute scope 1 and 2 GHG emissions 46.2% by 2030 from a 2019 base year.* Merck & Co., Inc., also commits to reduce absolute scope 3 GHG emissions 30% within the same timeframe.* *The target boundary includes land-related emissions and removals from bioenergy feedstocks. Long-Term Targets: Merck & Co., Inc., Rahway, New Jersey, U.S.A., which is known as MSD outside the U.S. and Canada commits to reduce absolute scope 1, 2 and 3 GHG emissions 90% by 2045 from a 2019 base year.* *The target boundary includes land-related emissions and removals from bioenergy feedstocks.

Net-Zero

Statut

Targets set

Année cible

2045

Progression37%
Business Ambition 1.5°C

Statut

BA1.5 member

Date d'engagement

16/03/2023

Classification détaillée

The targets covering greenhouse gas emissions from company operations (scopes 1 and 2) are consistent with reductions required to keep warming to 1.5°C

Identifiants

ISIN

US58933Y1055

LEI

4YV9Y5M8S0BRK1RP0397

Source : Science Based Targets initiative | Données publiques